Synergistic Activity of Equol and Meropenem against Carbapenem-Resistant Escherichia coli
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hye-Rim | - |
dc.contributor.author | Eom, Yong-Bin | - |
dc.date.accessioned | 2021-08-11T08:30:06Z | - |
dc.date.available | 2021-08-11T08:30:06Z | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 2079-6382 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2059 | - |
dc.description.abstract | The emergence of carbapenem-resistant Enterobacterales (CRE) seriously limits treatment options for bacterial infections. Combined drugs are an effective strategy to treat these resistant strains. This study aimed to evaluate the synergistic effect of equol and meropenem against carbapenem-resistant Escherichia coli. First, this study investigated the antibacterial activity of carbapenems on clinically isolated E. coli strains by analyzing the minimum inhibitory concentrations (MICs). The E. coli strains were all resistant to carbapenem antibiotics. Therefore, we confirmed the cause of carbapenem resistance by detecting bla(KPC) and bla(OXA-48) among the carbapenemase genes using polymerase chain reaction (PCR) analysis. Checkerboard and time-kill analyses confirmed that equol restored the susceptibility of carbapenem-resistant E. coli to meropenem. Also, the transcription levels of specific carbapenemase genes in E. coli were significantly suppressed by equol. The study also evaluated the anti-virulence effects of equol on bacterial biofilm and motility through phenotypic and genotypic analyses. In conclusion, our results revealed that equol had a synergistic effect with meropenem on carbapenem-resistant E. coli. Therefore, this study suggests that equol is a promising antibiotic adjuvant that prevents the expression of carbapenemases and virulence factors in carbapenem-resistant E. coli. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | Synergistic Activity of Equol and Meropenem against Carbapenem-Resistant Escherichia coli | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/antibiotics10020161 | - |
dc.identifier.scopusid | 2-s2.0-85101087150 | - |
dc.identifier.wosid | 000622016800001 | - |
dc.identifier.bibliographicCitation | Antibiotics, v.10, no.2 | - |
dc.citation.title | Antibiotics | - |
dc.citation.volume | 10 | - |
dc.citation.number | 2 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ESTROGEN-RECEPTOR-BETA | - |
dc.subject.keywordPlus | COMPLEX INTERPLAY | - |
dc.subject.keywordPlus | S-EQUOL | - |
dc.subject.keywordPlus | ENTEROBACTERIACEAE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | MOTILITY | - |
dc.subject.keywordPlus | PCR | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordAuthor | equol | - |
dc.subject.keywordAuthor | carbapenem-resistant Escherichia coli | - |
dc.subject.keywordAuthor | anti-bacterial | - |
dc.subject.keywordAuthor | anti-virulence | - |
dc.subject.keywordAuthor | synergistic activity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.